Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel in Localized Prostate Cancer
NCT00598858Phase 2Withdrawn
- Start
- Jan 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa). Primary endpoint: Prostate-Specific Antigen Response Rate at 9 weeks. Planned start Jan 2009; status: withdrawn.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00598858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00598858.